DESC:FIELD OF THE INVENTION
The present invention relates to novel stable crystalline form of Rucaparib (I) camsylate and methods of preparing the same

The present invention further relates to process for the amorphous Rucaparib(I) camsylate.

The process disclosed for the preparation of crystalline and amorphous forms of Rucaparib (I) camsylate is commercially viable and lead to consistently produce as the stable material.

BACKGROUND OF THE INVENTION
Rucaparib is chemically known as 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one.

Rucaparib and its pharmaceutically acceptable salts are used as an inhibitor of the nuclear enzyme polyadenosine 5’-diphosphoribose (poly-ADP-ribose) polymerase (PARP), with chemosensitizing, radiosensitizing, and antineoplastic activities. Upon administration, Rucaparib camsylate selectively binds to PARP-1, PARP-2 and PARP-3, and inhibits PARP1-mediated repair of single-strand DNA (ssDNA) breaks via the base-excision repair pathway; this enhances the accumulation of DNA strand breaks and promotes genomic instability and apoptosis. Rucaparib camsylate may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by ssDNA breaks.

Rucaparib camsylate salt was approved by USFDA in Dec 19, 2016 and is marketed under the brand name RUBRACA and is indicated for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.

Rucaparib Camsylate is marketed in a crystalline form. It is a white to pale yellow powder, formulated into a tablet for oral use, shows pH independent low solubility of approximately 1mg/mL across the physiological pH range. The chemical formula of rucaparib camsylate is C19H18FN3O•C10H16O4S and the relative molecular mass is 555.67 Daltons.

Rucaparib is specifically anticipated by Stephen Evan Webber et al in US 6495541 B2. The compound Rucaparib has valuable pharmacological properties and can be used, as potent poly (ADP-ribosyl) transferase (PARP) inhibitors and is useful as therapeutics, especially in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used in combination with DNA-damaging cytotoxic agents for example, topotecan, irinotecan, or temozolomide, and/or radiation. The process for the preparation of Rucaparib is delineated below.

In view of the above process, there are several drawbacks found in the process for preparing rucaparib i.e. there were significant thermal hazards present during Leimgruber-Batcho indole synthesis, low yielding side-chain installation, a non-robust Suzuki coupling and hydrogen cyanide generation during a reductive amination, which appears to be unsafe and cumbersome and thus it was apparent to develop a commercially viable process/or crystallization process resulting in the acceptable product.

Chunrong Ma et al in US7323562B2 disclose an alternative and convergent process for preparation of tricyclic inhibitor of poly (ADP-ribose) polymerase (PARP). In addition, according to Chunrong teachings Rucaparib was prepared via sonogashira coupling reaction and a CUI-promoted indole formation would be desirable to have an alternative convergent route for eventual commercial manufacturing. The process for the preparation of Rucaparib was schematically represented as below
This patent has not provided any insight about the impurity concern as well as solid state and purity of the final product of Rucaparib.

Adam Gillmore et al in Organic Process Research & Development, 2012 article disclosed various process and multikilogram scale up for Novel PARP inhibitor Rucaparib process and formation of new salt Rucaparib camyslate thereof.

The process for the preparation of Rucaparib was schematically represented as below

Canan-Koch et al in WO2004087713A1 disclosed phosphate salt of Rucaparib. However, this patent application not disclosed crystalline nature of Rucaparib phosphate salt.

Liu et al in US7268126 disclosed Rucaparib amorphous and crystalline forms of phosphate salt namely Form I(Hydrate A), Form II (Anhydrous), Form III (Hydrate B), Form V (hydrate C), Form VI, Form IV (MeOH solvate).

Basford et al in US8754072B2 disclosed various camsylate and maleate salts of Rucaparib. This patent particularly disclosed two maleate forms of Rucaparib designated as Form A and Form B. The patent further disclosed camyslate salts, among them one salt form is S-camyslate salts which exists in three forms designated as Form A, Form B, Form C and other is R-camsylate salt exist in single crystalline form designated as form A respectively.

The conversion of one polymorphic form into another polymorphic form can be unfavorable in pharmaceutical dosage forms such as tablets, often resulting in different hygroscopicity, dissolution and pharmacokinetic properties. As a result thereof, the bioavailability of the active agent might be undesirably unpredictable. Consequently, active agents having different interchangeable polymorphs may lead to regulatory and commercial disadvantages since they very often do not fulfill the requirements of the corresponding regulation authorities such as the FDA and EMEA.

In view of the above it is pertinent to note that there exists an inherent need to develop stable crystalline form of Rucaparib camsylate having further improved physical and/or chemical properties besides high purity levels. Hence it was thought worthwhile by the inventors of the present application to explore novel process/crystallization process for the preparation of Rucaparib camsylate, which may further improve the characteristics of drug Rucaparib camsylate and in developing the substantially pure stable crystalline form of Rucaparib camsylate consistently obtainable and amenable to scale-up.

As polymorphism has been given importance in the recent literatures owing to its relevance to the drugs having oral dosage forms due to its apparent relation to dose preparation/suitability in composition steps/bioavailability and other pharmaceutical profiles, stable polymorphic form of a drug has often remained the clear choice in composition due to various reason of handling, mixing and further processing including bioavailability and stability.

Exploring new polymorphic form for developing a stable and pure form of Rucaparib Camsylate which is amenable to scale up for pharmaceutically active useful compounds in the preparation of Rucaparib camsylate may thus provide an opportunity to improve the drug performance characteristics of products such as purity and solubility. Hence, inventors of the present application report a new polymorphic form, which is a stable and substantially pure form of Rucaparib camsylate, which may be industrially amenable and usable for preparing the corresponding pharmaceutical compositions.

In view of above and overcome the prior art problems the present inventors had now developed a new polymorphic form of Rucaparib camsylate. It was apparent to develop a process/or crystallization process resulting in the product, which is complying with the ICH requirements of quality parameters. Rucaparib camsylate crystalline material was obtained by the process of the present invention is chemically stable and has been found with good dissolution properties.

OBJECTIVE OF THE INVENTION
The main objective of the invention relates to new stable polymorphic form of Rucaparib camsylate.
Yet another objective of the invention relates to crystalline form of Rucaparib camsylate, which is a stable and substantially pure form of Rucaparib camsylate, which may be industrially amenable and usable for preparing the corresponding pharmaceutical compositions.
Yet another objective of the invention relates a process for the preparation of crystalline form of Rucaparib camsylate.
Yet another objective of the invention relates a process for the preparation of amorphous form of Rucaparib camsylate, which is free of process related impurities.

SUMMARY OF THE INVENTION
Aspects of the present invention relates to the new stable polymorphic form of Rucaparib camsylate.

In another aspect of the present invention relates to Crystalline Rucaparib Camsylate characterized by X-ray powder diffraction pattern comprising 2?° peaks selected from 11.8, 13.0, 13.4, 15.7, 17.7, 20.7, 21.4, 23.5, 24.7 and 28.0 ±0.2 2?° designated as Form-SRC.

In another aspect of the present invention relates to Crystalline Rucaparib Camsylate characterized by DSC isotherm comprising endothermic peak ranging between 285 to 295°C.

In another aspect of the present invention relates to a process for the preparation of amorphous Rucaparib camsylate, comprising the steps of:
a) dissolving Rucaparib camsylate in an alcohol solvent; and
b) isolating amorphous Rucaparib camsylate

BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is an example of X-ray powder diffraction (“XRPD”) pattern of Crystalline Rucaparib Camsylate Form-SRC obtained according the present invention.
Fig. 2 is an example of DSC thermogram of Crystalline Rucaparib Camsylate Form-SRC obtained according the present invention.
Fig. 3 is an example of TGA thermogram of Crystalline Rucaparib Camsylate Form-SRC obtained according the present invention.
Fig. 4 is an example of X-ray powder diffraction (“XRPD”) pattern of amorphous Rucaparib Camsylate obtained according the present invention.

DETAILED DESCRIPTION OF THE INVENTION
Although several polymorphs of Rucaparib camsylate have been identified and well known in the literature, each polymorphic form can be distinguished using several different analytical parameters, alone or in combination, such as, but not limited to, powder X-ray diffraction pattern peaks or combinations of two or more peaks. However, the present inventors now developed a new stable crystalline polymorphic form, which are different from the prior-art polymorphic forms disclosed in the literature.

In one embodiment of the present invention relates to a Crystalline Rucaparib Camsylate characterized by X-ray powder diffraction pattern comprising 2?° peaks selected from 11.8, 13.0, 13.4, 15.7, 17.7, 20.7, 21.4, 23.5, 24.7 and 28.0 ±0.2 2?°.

Crystalline Rucaparib Camsylate is further characterized by X-ray powder diffraction pattern comprising at 2?° peaks selected from 13.9, 15.0, 16.5, 18.5, 20.5, 22.9, 24.1 and 25.9 ±0.2 2?°.

Crystalline Rucaparib Camsylate is further characterized by DSC thermogram comprising endothermic peak ranging between 285 to 295°C.

The crystalline Rucaparib Camsylate disclosed in the present invention is designated as Form-SRC. The word “Camsylate” referred in this present application is (S)-camsylate

The present invention further provides a process for the preparation of Crystalline Rucaparib Camsylate Form-SRC X-ray powder diffraction pattern comprising 2?° peaks selected from 11.8, 13.0, 13.4, 15.7, 17.7, 20.7, 21.4, 23.5, 24.7 and 28.0 ±0.2 2?°, wherein process comprising heating Rucaparib camsylate in a petri dish and kept in a programmable hot air oven at 200 -250°C for a period of 10 minutes to 40 minutes.

Crystalline Rucaparib Camsylate Form-SRC obtained by the above process is anhydrous and having a moisture content of less than 1.0 %. The crystalline Rucaparib Camsylate Form-SRC obtained by this process is stable and free of process related impurities.

In an another embodiment of the present invention further provides a process for the preparation of Crystalline Rucaparib Camsylate Form-SRC X-ray powder diffraction pattern comprising 2?° peaks selected from 11.8, 13.0, 13.4, 15.7, 17.7, 20.7, 21.4, 23.5, 24.7 and 28.0 ±0.2 2?°, wherein process comprising heating amorphous Rucaparib camsylate in a petri dish and kept in a programmable hot air oven at 200 -250°C for a period of 10 minutes to 40 minutes.

In an another embodiment of the present invention relates to process for the preparation of crystalline Rucaparib Camsylate Form-SRC by dissolving any form of Rucaparib camsylate in a solvent followed by seeding with crystalline Rucaparib Camsylate Form-SRC obtained according to process as disclosed.

Rucaparib camsylate used for the preparation of crystalline Rucaparib camsylate Form –SRC may be crystalline or amorphous or a solvate thereof.

In an another embodiment of the present invention relates to process for the preparation of crystalline Rucaparib Camsylate Form-SRC by dissolving crystalline or amorphous of Rucaparib camsylate in one or more solvent selected from alcohol, ketone, ester, halogenated hydrocarbon, polar aprotic solvent, acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane or mixtures thereof; wherein alcohol is selected from methanol, ethanol, isopropanol, 2-propanol, 1-butanol, t-butyl alcohol, 1- pentanol, and 2-pentanol; the ketone is selected from acetone, butanone, 2- pentanone, 3-pentanone, methylbutyl ketone, and methyl isobutyl ketone; the ester is selected from ethyl acetate, propyl acetate, isopropyl acetate, t-butyl acetate, and isobutyl acetate; and the halogenated hydrocarbon is selected from methylene dichloride, ethylene dichloride, carbon tetrachloride and chlorobenzene; polar aprotic solvent selected from dimethylformamide, dimethylsulfoxide, and N-methyl- pyrrolidone; followed by seeding with crystalline Rucaparib Camsylate Form-SRC obtained according to process disclosed above.

The Crystalline Rucaparib Camsylate Form-SRC obtained by the above process is anhydrous and having a moisture content of less than 1.0 %. Crystalline Rucaparib Camsylate Form-SRC obtained by this process is stable and free of process related impurities.

The present inventors analyzed Crystalline Rucaparib Camsylate Form-SRC for hygroscopic study. However, the present inventors found that the Crystalline Rucaparib Camsylate Form-SRC obtained by the present invention appears to be low hygroscopic.

Further, the study of Crystalline Rucaparib Camsylate Form-SRC at 90% relative humidity in desiccator at 25°C containing saturated potassium chloride solution are kept in glass petri-dish and placed it into desiccator, the samples were withdrawn and analyzed at different time intervals, and the results appears low hygroscopic

Further embodiment of the present invention provides Crystalline Rucaparib Camsylate Form-SRC obtained by the present invention is free of other polymorphic impurities, wherein said crystalline form is present in a solid form greater than 99.9 % by weight.

Crystalline Rucaparib Camsylate Form-SRC is found to be a very stable crystal lattice which is adequately stable to handle and store for longer time without any significant or measurable change in its morphology and physicochemical characteristics. Crystalline Rucaparib Camsylate Form-SRC retains its nature even on exposure to uncontrolled environmental conditions. This stable form thus, offers various advantages in terms of storage, shelf life and favorable impurity profile.

Any form of Crude or Pure Rucaparib Camsylate obtained by any process may be used for preparing Crystalline Rucaparib Camsylate Form-SRC. Crystalline Rucaparib Camsylate Form-SRC of the present invention may have one or more advantages and desirable properties compared to the known Crystalline Rucaparib Camsylate forms, which are not limited to better stability, hygroscopicity, high solubility and high purity leading to improved storage and distribution.

The process related impurities, including degradation products and other medium dependent impurities like residual solvent, that appear in the impurity profile of the Rucaparib Camsylate can be substantially removed by the process of the present invention resulting in the formation pure Crystalline Rucaparib Camsylate Form-SRC. A substantially pure product i.e. Crystalline Rucaparib Camsylate Form-SRC having purity more than 99.9% (by HPLC) can be obtained in high yield by the process of the present invention.

The Crystalline Rucaparib Camsylate Form-SRC described herein may be characterized by X-ray powder diffraction pattern (XRPD) and Thermal techniques such as differential scanning calorimetric (DSC) Analysis and TGA. The samples of Crystalline Rucaparib Camsylate Form-SRC were analyzed by XRPD on a Bruker AXS D8 Advance Diffractometer using X-ray source - Cu Ka radiation using the wavelength 1.5418 Å. DSC was done on a TA DSC Q2000 instrument measured at a heating rate of 10°C/min and TGA on a Perkin Elmer TGA 4000 instrument. Illustrative example of analytical data for the Crystalline Rucaparib Camsylate Form-SRC obtained in the Examples is set forth in the Figures 1-3.

In another embodiment of the present invention relates to a process for the preparation of amorphous Rucaparib camsylate, comprising the steps of:
a) dissolving Rucaparib camsylate in an alcohol solvent; and
b) isolating amorphous Rucaparib camsylate

In another embodiment of the present invention relates to a process for the preparation of amorphous Rucaparib camsylate, comprising dissolving crystalline or amorphous form of Rucaparib camsylate in a solvent selected from C1-C5 alcohols such as methanol, ethanol, isopropanol, 2-propanol, 1-butanol, t-butyl alcohol, 1- pentanol, 2,2,2-trifluoroethanol and 2-pentanol at a temperature ranging from 25-300C. The reaction mixture was stirred for 5 minutes to 30 minutes and filtered directly using any of evaporation technique such as distillation using a rotational evaporator, freeze drying (lyophilization), spray drying and agitated thin film drying (ATFD) to yield amorphous form of Rucaparib having PXRD pattern according to FIG. 4.

The obtained pure Rucaparib camsylate was analyzed, if it is not matching with the desired purity; again repeat the process by treating Rucaparib camsylate with a solvent, followed by distillation to obtain substantially pure Rucaparib camsylate having a purity of greater than 99.5% and meeting the ICH guidelines.

The use of pure Rucaparib camsylate in the preparation of new polymorphic form parallel results in the formation of substantially pure crystalline form of Rucaparib camsylate having a purity of greater than 99.5 %, wherein substantially pure Rucaparib camsylate is having an impurity profile meeting the ICH guidelines. The polymorph related impurities formed during the crystallization of crude Rucaparib camsylate has been successfully removed by the present process, which yields in the formation of highly pure crystalline or amorphous forms of Rucaparib camsylate

Another embodiment of the present invention relates to substantially pure crystalline Rucaparib camsylate having a purity of greater than 99.5 %, wherein substantially pure Rucaparib camsylate contains the process related impurities collectively below 0.3% area percentage by HPLC and meeting the ICH guidelines.

The process related impurities that appear in the impurity profile of the Rucaparib camsylate (I) may be substantially removed by the process of the present invention resulting in the formation of substantially Rucaparib camsylate (I), which meets the ICH guidelines.

The merit of the process according to the present invention resides in that product isolated after drying is stable and having a purity of greater than 99.5% purity by HPLC, which was not disclosed in any of the prior-art. The product obtained as per the present invention is highly pure than any of the prior-art products obtained. No prior publication discloses a purity of greater than 99.5%.

Solubility is one of the important parameters to achieve desired concentration of drug in systemic circulation for achieving required pharmacological response. Poorly water soluble drugs often require high doses in order to reach therapeutic plasma concentrations after oral administration. Low aqueous solubility is the major problem encountered with formulation development of new chemical entities as well as generic formulation development. Most of the drugs are either weakly acidic or weakly basic having poor aqueous solubility. The improvement of drug solubility thereby its oral bio-availability remains one of the most challenging aspects of drug development process especially for oral-drug delivery system. The poor solubility and low dissolution rate of poorly water soluble drugs in the aqueous gastrointestinal fluids often cause insufficient bioavailability. The enhancement in the purity of Rucaparib camsylate and crystalline arrangement of novel polymorphic form (Rucaparib camsylate Form-SRC) which is free of process related impurities inherently increases the solubility of Rucaparib camsylate, which plays a major role for enhancement of drug dissolution rate in solid oral dosage forms.

The present invention also relates to a process for the preparation of Rucaparib camsylate, which is substantially pure having a purity of greater 99.5 % and meeting the ICH guidelines, by limiting the content of each impurity less than 0.3%. Further, the Rucaparib camsylate obtained as per the present process is found devoid of any other process related impurities and is adequately stable to handle and store for longer time (at least up to more than 6 months) without any significant or measurable change in its morphology and physicochemical characteristics.

Drying may also be performed by any conventional process not limited to spray drying or distillation to remove the solvent. Drying may be performed under reduced pressure conditions also. Reduced pressure conditions may be suitably utilized by person skilled in the art in order to obtain the dried material. The drying may be performed at a temperature ranging from 50-85°C for a time ranging from 5 to 10 hours depending upon the physical attributes of the end product obtained i.e. Pure Rucaparib camsylate, which is obtained according to the present invention is having purity greater than 99.5%.

In another embodiment of the present invention the substantially pure Rucaparib camsylate obtained by the processes of the present application may be taken as such in crystalline form for manufacture of solid dosage forms like tablets, capsules and/or for manufacture of oral liquids.

In another embodiment of the present invention the substantially pure crystalline form of Rucaparib camsylate (Rucaparib camsylate Form-SRC) obtained by the processes of the present application may be manufactured as the amorphous form by processing with polymers like hydroxypropyl methylcellulose acetate succinate (HPMC-AS).

In another embodiment, the substantially pure crystalline form of Rucaparib camsylate (Rucaparib camsylate Form-SRC) obtained by the processes of the present application may be formulated as solid compositions for oral administration in the form of capsules, tablets, pills, powders or granules. In these compositions, the active product is mixed with one or more pharmaceutically acceptable excipients. The drug substance can be formulated as liquid compositions for oral administration including solutions, suspensions, syrups, elixirs and emulsions, containing solvents or vehicles such as water, sorbitol, glycerin, propylene glycol or liquid paraffin.

In one embodiment of the present invention, it also includes premix comprising one or more pharmaceutically acceptable excipients in the range of 1 to 50% w/w with the substantially pure Rucaparib camsylate or its acid addition salt, while retaining the crystalline nature of the premix.

The compositions for parenteral administration can be suspensions, emulsions or aqueous or non-aqueous sterile solutions. As a solvent or vehicle, propylene glycol, polyethylene glycol, vegetable oils, especially olive oil, and injectable organic esters, e.g. ethyl oleate, may be employed. These compositions can contain adjuvants, especially wetting, emulsifying and dispersing agents. The sterilization may be carried out in several ways, e.g. using a bacteriological filter, by incorporating sterilizing agents in the composition, by irradiation or by heating. They may be prepared in the form of sterile compositions, which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
Pharmaceutically acceptable excipients used in the compositions comprising substantially pure Rucaparib camsylate or its acid addition salt obtained as per the present application process- include, but are not limited to diluents such as starch, pregelatinized starch, lactose, powdered cellulose, microcrystalline cellulose, di-calcium phosphate, tri-calcium phosphate, mannitol, sorbitol, sugar and the like; binders such as acacia, guar gum, tragacanth, gelatin, pre-gelatinized starch and the like; disintegrants such as starch, sodium starch glycolate, pregelatinized starch, Croscarmellose sodium, colloidal silicon dioxide and the like; lubricants such as stearic acid, magnesium stearate, zinc stearate and the like; glidants such as colloidal silicon dioxide and the like; solubility or wetting enhancers such as anionic or cationic or neutral surfactants, waxes and the like. Other pharmaceutically acceptable excipients that are of use include but not limited to film formers, plasticizers, colorants, flavoring agents, sweeteners, viscosity enhancers, preservatives, antioxidants and the like.

Pharmaceutically acceptable excipients used in the compositions derived from substantially pure Rucaparib camsylate or its acid addition salt of the present application may also comprise to include the pharmaceutically acceptable carrier used for the preparation of solid dispersion, wherever utilized in the desired dosage form preparation.

The following examples illustrate the nature of the invention and are provided for illustrative purposes only and should not be construed to limit the scope of the invention.

EXAMPLES

Example-1
Process for preparation of amorphous form of Rucaparib camsylate:
Rucaparib camsylate (500 mg, 0.0009mol) was charged into a reaction flask containing methanol (100 mL) at 25-300C. The reaction mixture was stirred for 5 minutes and filtered directly into a Buchi rotavapor flask. The filtrate obtained was distilled out at 600C under vacuum with step-wise decrease of pressure from 916 mbar to 400 mbar for the first 30 minutes and at 50 mbar pressure for the next 120 minutes to yield amorphous form of Rucaparib having PXRD pattern according to FIG. 4.
Yield: 300 mg

Example-2
Process for preparation of amorphous form of Rucaparib camsylate:
Rucaparib camsylate (14.0 g, 0.025 mol) was charged into a reaction flask containing 2,2,2-Trifluoroethanol (210.0 mL) at 25-30°C. The reaction mixture was stirred for 5 minutes and filtered directly into a Buchi rotavapor flask. The filtrate obtained was distilled out at 45-50°C under vacuum to yield amorphous form of Rucaparib camsylate.
Yield: 13 g

Example-3
Process for preparation of crystalline form of Rucaparib camsylate:
Amorphous Rucaparib camsylate (250 mg, 0.00045 mol) obtained from above example was taken in a petri-dish and kept in a programmable hot air oven at 2400C for 30 minutes to yield crystalline form of Rucaparib having PXRD pattern according to FIG. 4.
Yield: 200 mg

Example-4
Process for preparation of crystalline form of Rucaparib camsylate:
Rucaparib camsylate (500 mg, 0.0008mol) was charged into a reaction flask containing methanol (10 mL) at 25-30°C. The reaction mixture was stirred for 5 minutes and heated to 60-65°C and stirred for 10 min then the reaction mixture was cooled to 45-50°C and seeded with Rucaparib camsylate obtained in example-3. The above reaction mixture was stirred for 30 min at 45-50°C and cooled to 25-30°C to yield crystalline of Rucaparib camsylate having PXRD pattern according to FIG. 4.
Yield: 350 mg

Example-5
Process for preparation of amorphous Rucaparib camsylate solid dispersion:
Rucaparib freebase (5.0 g, 0.0154 mol) was charged in to flask containing acetone (50.0 mL) and DM water (50.0 mL) at 25-35°C. The reaction mixture was stirred for 10 minutes. Charged S-Camphor sulphonic acid (3.75 g, 0.0161 mol). Stirred the reaction mass for 10 minutes at 25-35°C. Charged Povidone (5.0 g) in to reaction mass at 25-35°C. Stirred the reaction mass for 10 minutes and filtered directly into a Buchi rotavapor flask. The filtrate obtained was distilled out at 45-50°C under vacuum to yield amorphous form of Rucaparib camsylate solid dispersion.
Yield: 9.6 g

While the foregoing pages provide a detailed description of the preferred embodiments of the invention, it is to be understood that the summary, description and examples are for illustrative purpose only of the core of the invention and non-limiting in their scope. Furthermore, as many changes may be made to the invention without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.
,CLAIMS:We Claim:
1) Crystalline Rucaparib Camsylate characterized by X-ray powder diffraction pattern comprising 2?° peaks selected from 11.8, 13.0, 13.4, 15.7, 17.7, 20.7, 21.4, 23.5, 24.7 and 28.0 ±0.2 2?°

2) Crystalline Rucaparib Camsylate according to claim 1, which is further characterized by X-ray powder diffraction pattern comprising 2?° peaks selected from 13.9, 15.0, 16.5, 18.5, 20.5, 22.9, 24.1 and 25.9 ±0.2 2?°

3) Crystalline Rucaparib Camsylate according to claim 1, further characterized by DSC isotherm comprising endothermic peak ranging between 285 to 295°C.

4) Crystalline Rucaparib Camsylate characterized by X-ray powder diffraction pattern comprising 2?° peaks selected from 11.8, 13.0, 13.4, 15.7, 17.7, 20.7, 21.4, 23.5, 24.7 and 28.0 ±0.2 2?°, wherein process comprising heating Rucaparib camsylate in a petri dish and kept in a programmable hot air oven at 200 -250°C for a period of 10 minutes to 40 minutes.

5) Crystalline Rucaparib Camsylate according to claim-4, wherein process Rucaparib camsylate used for the preparation selected from any of the known crystalline or amorphous forms.

6) A process for the preparation of amorphous Rucaparib camsylate, comprising the steps of:
a) dissolving Rucaparib camsylate in an alcohol solvent; and
b) isolating amorphous Rucaparib camsylate

7) A process for the preparation of amorphous Rucaparib camsylate according to claim 6, wherein alcohol used is selected from C1-C5 alcohols.
8) A process for the preparation of amorphous Rucaparib camsylate according to claim 6, wherein alcohol used is selected from methanol, ethanol, isopropanol, 2-propanol, 1-butanol, t-butyl alcohol, 1- pentanol, 2,2,2-trifluoroethanol and 2-pentanol.

9) A process for the preparation of amorphous Rucaparib camsylate according to claim 6, wherein isolating amorphous form of Rucaparib camsylate is by solvent evaporation technique.

10) A process for the preparation of amorphous Rucaparib camsylate according to claim 6, wherein solvent evaporation technique such as distillation using a rotational evaporator, freeze drying (lyophilization), spray drying and agitated thin film drying (ATFD) are used.